Market Overview

UPDATE: Bank Of America Reiterates On McKesson Ahead Of 4Q14 EPS

Share:
Related MCK
Worst Performing Industries For May 23, 2016
McKesson And Walmart Reveal Sourcing Deal For Generic Pharmaceuticals
The Vetr community has downgraded $MCK to 3.5-Stars (Vetr)

In a report published Tuesday, Bank of America analyst Robert M. Willoughby reiterated an Underperform rating on McKesson (NYSE: MCK), and raised the price target from $160.00 to $165.00.

In the report, Bank of America noted, “Rebounding profitability in MCK's core drug wholesaling operations, traction for its ancillary franchises, and capital deployment initiatives should drive industry-leading earnings growth over a leaner infrastructure. However, at valuation highs following the announcement of its Celesio acquisition, we see more attractive investment opportunities elsewhere.”

McKesson closed on Monday at $174.23.

Latest Ratings for MCK

DateFirmActionFromTo
May 2016Avondale PartnersDowngradesMarket OutperformMarket Perform
Apr 2016Standpoint ResearchDowngradesBuyHold
Apr 2016Avondale PartnersInitiates Coverage onMarket Perform

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Bank of America Robert M. WilloughbyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MCK)

View Comments and Join the Discussion!